Results 11 to 20 of about 939 (187)

Efficacy of lasmiditan, rimegepant and ubrogepant for acute treatment of migraine in triptan insufficient responders: systematic review and network meta-analysis [PDF]

The Journal of Headache and Pain
Background Novel abortive treatments for migraine, ditans and gepants, have promising implications in triptan-insufficient responders with minimal existing comparative data.
Wattakorn Laohapiboolrattana, Priabprat Jansem, Prakit Anukoolwittaya, Duangnapa Roongpiboonsopit, Akarin Hiransuthikul, Thanakit Pongpitakmetha, Sekh Thanprasertsuk, Wanakorn Rattanawong   +7 more
doaj   +3 more sources

Mechanistic Investigations Support Liver Safety of Ubrogepant [PDF]

Toxicological Sciences, 2020
Abstract Small-molecule calcitonin gene-related peptide (CGRP) receptor antagonists have demonstrated therapeutic efficacy for the treatment of migraine. However, previously investigated CGRP receptor antagonists, telcagepant and MK-3207, were discontinued during clinical development because of concerns about drug-induced liver injury. A
Smith, Brenda, Sistare, Frank D, Watkins, Paul B, Rowe, Josh, Goadsby, Peter J, Woodhead, Jeffrey L, Ashina, Messoud   +6 more
openaire   +4 more sources

Ubrogepant: First Approval [PDF]

Drugs, 2020
AbstractUbrogepant (Ubrelvy™) is an orally administered, small molecule, highly-selective, calcitonin gene-related peptide (CGRP) antagonist that was developed by Allergan under license to Merck & Co. as an acute treatment for migraine. In December 2019, ubrogepant received its first global approval in the USA for the acute treatment of migraine (± 
Lesley J. Scott (4891801)
openaire   +3 more sources

Ubrogepant and rimegepant: systematic review, meta-analysis, and meta-regression of clinical studies

Expert Opinion on Drug Safety, 2023
This study aimed at providing pooled estimates of the incidence of adverse drug reactions (ADRs) of ubrogepant and rimegepant and to use meta-regression to identify correlations between the occurrence of selected ADRs, socio-demographic, and clinical characteristics from data published in clinical studies.
Guojun Dong, Naoko Adachi Kjærgaard, Saeed Shakibfar, Maurizio Sessa   +3 more
core   +6 more sources

A Short on Ubrogepant

Journal of Pharmaceutical Research International, 2021
Migraine is a mysterious disorder characterized by pulsating head ache, which is actually characterized to one side and comes in attacks which will be lasting for about 3-48 hours and can be associated with nausea,vomiting,sensitivity to sound,flashes of light,vertigoand diarrhoea [1].
J. Mohan, S. Padmaja
openaire   +3 more sources

Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications [PDF]

Cephalalgia, 2020
Background The full utility of an acute treatment requires examination of the entire time course of effect during a migraine attack. Here the time course of effect of ubrogepant is evaluated. Methods ACHIEVE-I ...
Peter J Goadsby, Andrew M Blumenfeld, Richard B Lipton, David W Dodick, Kavita Kalidas, Aubrey M Adams, Abhijeet Jakate, Chengcheng Liu, Armin Szegedi, Joel M Trugman   +9 more
openaire   +4 more sources

Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis [PDF]

Headache: The Journal of Head and Face Pain, 2021
Abstract Objective To determine the potential efficacy of ubrogepant for acute treatment of migraine based on historical experience with triptans. Background Although triptans have improved migraine treatment, their ...
Andrew M. Blumenfeld, Peter J. Goadsby, David W. Dodick, Susan Hutchinson, Chengcheng Liu, Michelle Finnegan, Joel M. Trugman, Armin Szegedi   +7 more
openaire   +4 more sources

Ubrogepant: a new era in migraine treatment [PDF]

International Journal of Basic & Clinical Pharmacology, 2020
Migraine is the most common neurological disorder that leads to incapacitating neurological symptoms. Acute attacks of migraine have been dealt with effectively with non-steroidal anti-inflammatory drugs (NSAIDs), ergot derivatives and triptans since long, but their use is limited by various adverse effects.
Sangeeta Bhanwra, Kaza Ahluwalia
openaire   +3 more sources

Ubrogepant: Mechanism of action, clinical and translational science

Clinical and Translational Science
In recent years, the treatment of migraine has experienced a breakthrough in the development of drugs that target the calcitonin gene‐related peptide (CGRP) signaling pathway.
Ramesh Boinpally, Mohamad Shebley, Joel Trugman   +2 more
doaj   +2 more sources

Blocking the CGRP Receptor: Differences across Human Vascular Beds [PDF]

Pharmaceuticals, 2023
Multiple drugs targeting the calcitonin gene-related peptide (CGRP) receptor have been developed for the treatment of migraine. Here, the effect of the small-molecule CGRP receptor antagonist zavegepant (0.1 nM–1 µM) on CGRP-induced relaxation in ...
Tessa de Vries, Deirdre M. Boucherie, Antoon van den Bogaerdt, A. H. Jan Danser, Antoinette MaassenVanDenBrink   +4 more
doaj   +2 more sources